Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy and Biomarkers in First-Line Metastatic Melanoma
NCT07407166Recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- May 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in melanoma, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Overall Response Rate at 28 weeks. Started May 2021; status: recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT07407166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407166.